Tradestie Institutional Equity Comparison Engine
MBX vs BU โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
MBX Overall Edge
MBX Captures Institutional Edge (3โ0 Pillars ยท 7โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MBX Biosciences, Inc. Common Stock (MBX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, MBX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BU at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, MBX sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against BU sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
MBX N/M vs BU N/M Fwd P/E
Growth & Margin Winner
MBX
Op Margin 0.0% vs N/A ยท YoY +0.0% vs N/A
Momentum & Technical Winner
MBX
1Y +120.7% vs -9.1% ยท 52W Pos 61% vs 6%
Options & Structure Winner
MBX
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
MBX
NASDAQ
MBX Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$53.12
-5.04% 1D
Market Cap
$2.8B
1M Return
+7.08%
1Y Return
+120.69%
Forward P/E
N/M
Unified AI Score
45.1 / 100
HOLD
Tech 42.0
Fund 48.0
Flow 50.0
Mom 54.0
BU
US Equity
BU
Institutional Equity
$18.17
+0.46% 1D
Market Cap
N/A
1M Return
-14.04%
1Y Return
-9.12%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 50.0
Mom 48.2
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MBX +120.69%
BU -9.12%
Spread: +15.0 pp (MBX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MBX TTM Op. Margin: 0.0%
BU TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBX vs BU. Trailing 12-month operating profitability (MBX 0.0% vs BU N/A) and valuation multiples (MBX N/M vs BU N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MBX | BU | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.8B | N/A | Larger Scale | MBX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | N/A | Higher Growth | MBX |
| Operating Margin (TTM) Profitability | 0.0% | N/A | Higher Margin | MBX |
| Net Profit Margin Profitability | 0.0% | N/A | Higher Margin | MBX |
| Return on Equity (ROE) Capital Efficiency | -33.7% | N/A | Higher ROE | MBX |
| 52-Week Range Position Momentum | 61% ($23โ$73) | 6% ($17โ$39) | Stronger Trend | MBX |
| Beta / 30D Volatility Risk Regime | 1.58ฮฒ ยท 66% Vol | 3.91ฮฒ ยท 97% Vol | Lower Realized Risk | MBX |
| Unified Institutional Score Composite Signal | 45.1 / 100 (HOLD) | 53.5 / 100 (HOLD) | Higher Composite | BU |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MBX vs BU Buy Guide
MBX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
BU
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MBX nor BU registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.